Life Science Investing Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Life Science Investing Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation
Life Science Investing Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Life Science Investing Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease
Life Science Investing Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Life Science Investing Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Life Science Investing Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Life Science Investing Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
Life Science Investing Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
Life Science Investing Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
Life Science Investing Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference
Freegold Ventures Limited Announces Upsized Brokered Private Placement Financing from $30 Million to Up to $50 Million
